COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas

For years, the analyst has covered the fields of molecular diagnostics, immunoassays, vaccines, and telehealth. These all find themselves both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements, and analysis from the analysis team on the fast-breaking events in the COVID-19 epidemic.

Particular sections address the most important market changes:

Molecular Diagnostics: It's important to note that the entire molecular testing concept originated in the midst of a crisis, at that time of the AIDS crisis, and has since been brought to bear on a number of emerging and mature infectious disease categories. COVID-19 has seen the molecular in vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndromic tests, high throughput systems and surge production on badly needed kits.

Immunoassays: Never have immunoassays been of such worldwide attention, as antibody tests are greatly sought. With this, come concerns about accuracy levels on broad populations and greater knowledge about development times. There are now immunoassays in development. We track these efforts and provide commentary on the role of these tests in a threat so far dominated by molecular diagnostics.

Vaccines: The analyst look at the vaccines in development and the struggles with vaccine discovery and manufacturing in other pandemics. Companies developing vaccines are featured.

Other Traditional IVDs: With many hospitals shut down across the globe, what is the impact and expected future of standard in vitro diagnostic testing? - from company statements made both publicly and directly to the analyst.

Remote Patient Monitoring: Already a healthcare trend that was catching on but perhaps struggling to convince payors of its critical necessity, remote patient monitoring, and telehealth transformed overnight with social distancing policies and relaxed HIPAA rules. But will market players be crowded out by traditional phone and web video companies?

This report does not seek to provide a data-driven market assessment due to the rapidly-changing situation but does provide analyst commentary that may assist customers needing to work out models. Some of the market estimates provide foundational bases on which to judge potential market impact. Commentary and analysis from the analysts who have studied markets in some cases for decades add understanding to the current, often chaotic, market atmosphere. Further publications and surveys from the analyst will provide additional market impact data.

No one company has the solution to COVID-19. Multiple companies have solutions to one problem or part of the solution, and companies are partnering to build strength and distribute products.

As part of its coverage, the report mentions the following companies:

• Abbott
• Amaro Lab of the University of California (UC), San Diego
• Avellino Lab USA
• BGI
• BioFire
• Biofourmis
• Boston Scientific
• Bruker
• Cepheid
• Clover
• Credo Diagnostics Biomedical
• Diagnostics for the Real World
• DiaSorin Molecular
• Dynavax
• Emerald Organic
• EpiGentek
• Fluxergy
• GE Healthcare
• Generation Bio
• Genetic Signatures
• GenMark Diagnostics
• Gilead Science
• Green Cross
• Hackensack Meridian Health, Center for Discovery and Innovation's (CDI)
• Henry Schein
• HiberGene Diagnostics
• Hologic
• JLK Inspection
• Johnson & Johnson (J&J)
• Kleo
• Laboratory Corporation of America (LabCorp)
• Luminex
• Medtronic
• Mesa Biotech
• Mobidiag
• Molbio Diagnostics
• NeuMoDx
• PerkinElmer
• Persivia
• Philips Medical
• Primer Design
• Qiagen
• QuantuMDx
• Quest
• Quidel
• Roche
• Surgisphere
• T2 Biosytems
• Thermo Fisher
• ThermoGenesis
• Todos Medical
• Vir
• Wadsworth Center, New York State Department of Health
• Xencor